Kimberly Walker

Kimberly Walker

Auto-generated profile, based on publicly available information

Kimberly Walker

Human Genome Sequencing Center, Baylor College of Medicine, Houston, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
EVEric Venner
Eric Venner
KPKarynne Patterson
Karynne Patterson
DKDivya Kalra
Divya Kalra
MWMarsha M. Wheeler
Marsha M. Wheeler
YCYi-Ju Chen
Yi-Ju Chen
RGRichard A. Gibbs
Richard A. Gibbs
Disparities in data underlying clinical genomic interpretation is an acknowledged problem, but there is a paucity of data demonstrating it. The All of Us Research Program is collecting data including whole-genome sequences, health records, and surveys for at least a million participants with diverse ancestry and access to healthcare, representing one of the largest biomedical research repositories of its kind. Here, we examine pathogenic and likely pathogenic variants that were identified in the All of Us cohort. The European ancestry subgroup showed the highest overall rate of pathogenic variation, with 2.26% of participants having a pathogenic variant. Other ancestry groups had lower rates of pathogenic variation, including 1.62% for the African ancestry group and 1.32% in the Latino/Admixed American ancestry group. Pathogenic variants were most frequently observed in genes related to Breast/Ovarian Cancer or Hypercholesterolemia. Variant frequencies in many genes were consistent with the data from the public gnomAD database, with some notable exceptions resolved using gnomAD subsets. Differences in pathogenic variant frequency observed between ancestral groups generally indicate biases of ascertainment of knowledge about those variants, but some deviations may be indicative of differences in disease prevalence. This work will allow targeted precision medicine efforts at revealed disparities.

13 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AHAndrew Haddad
Andrew Haddad
ARAparna Radhakrishnan
Aparna Radhakrishnan
SMSean McGee
Sean McGee
JSJoshua D. Smith
Joshua D. Smith
JKJason H. Karnes
Jason H. Karnes
PEPhilip Empey
Philip Empey
Pharmacogenomics promises improved outcomes through individualized prescribing. However, the lack of diversity in studies impedes clinical translation and equitable application of precision medicine. We evaluated the frequencies of PGx variants, predicted phenotypes, and medication exposures using whole genome sequencing and EHR data from nearly 100k diverse All of Us Research Program participants. We report 100% of participants carried at least one pharmacogenomics variant and nearly all (99.13%) had a predicted phenotype with prescribing recommendations. Clinical impact was high with over 20% having both an actionable phenotype and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance. Importantly, we also report hundreds of alleles and predicted phenotypes that deviate from known frequencies and/or were previously unreported, including within admixed American and African ancestry groups.

16 May 2022 in F1000Research
Verified
Journal Article
Open access
PDF file
KWKimberly Walker
Kimberly Walker
DKDivya Kalra
Divya Kalra
RLRebecca Lowdon
Rebecca Lowdon
GCGuangyi Chen
Guangyi Chen
DMDavid Molik
David Molik
BBBen Busby
Ben Busby
In October 2021, 59 scientists from 14 countries and 13 U.S. states collaborated virtually in the Third Annual Baylor College of Medicine & DNANexus Structural Variation hackathon. The goal of the hackathon was to advance research on structural variants (SVs) by prototyping and iterating on open-source software. This led to nine hackathon projects focused on diverse genomics research interests, including various SV discovery and genotyping methods, SV sequence reconstruction, and clinically relevant structural variation, including SARS-CoV-2 variants. Repositories for the projects that participated in the hackathon are available at https://github.com/collaborativebioinformatics.

26 March 2021 in F1000Research
Verified
Journal Article
Open access
PDF file
ACAnn M. Mc Cartney
Ann M. Mc Cartney
MMMedhat Mahmoud
Medhat Mahmoud
MJMichael Jochum
Michael Jochum
DADaniel Paiva Agustinho
Daniel Paiva Agustinho
BZBarry Zorman
Barry Zorman
FSFritz Sedlazeck
Fritz Sedlazeck
In October 2020, 62 scientists from nine nations worked together remotely in the Second Baylor College of Medicine & DNAnexus hackathon, focusing on different related topics on Structural Variation, Pan-genomes, and SARS-CoV-2 related research. The overarching focus was to assess the current status of the field and identify the remaining challenges. Furthermore, how to combine the strengths of the different interests to drive research and method development forward. Over the four days, eight groups each designed and developed new open-source methods to improve the identification and analysis of variations among species, including humans and SARS-CoV-2. These included improvements in SV calling, genotyping, annotations and filtering. Together with advancements in benchmarking existing methods. Furthermore, groups focused on the diversity of SARS-CoV-2. Daily discussion summary and methods are available publicly at https://github.com/collaborativebioinformatics provides valuable insights for both participants and the research community.

14 October 2025 in bioRxiv
Verified
Preprint
Open access
YHYoo-Jin Jiny Ha
Yoo-Jin Jiny Ha
DMDominika Maziec
Dominika Maziec
JMJulia Markowski
Julia Markowski
SGStephanie J. Georges
Stephanie J. Georges
NPNancy L. Parmalee
Nancy L. Parmalee
PPPeter Park
Peter Park
Mosaic mutations in normal tissues occur at low variant allele fractions (VAFs), complicating detection. To benchmark strategies, the SMaHT Network created a cell-line mixture (1:49) and produced ultra-deep whole-genome sequencing using short and long reads (five centers, 180–500× each). We assembled a reference of 44,008 mosaic SNVs and 2,059 Indels, cross-validation between platforms to expose limits of short-read analysis. We also partitioned the genome by mappability to examine the impact of genomic context, added a negative reference set, and accounted for culture-derived mutations. When seven institutions applied eleven algorithms to mixture data, call sets were largely discordant across tools and replicates, partly reflecting stochastic presence of low-VAF mutations in biological replicants. For >2% VAF SNVs, sensitivity and precision approached ∼80% at ≥300×, with little gain from additional sequencing. This work provides a comprehensive framework for reliable detection of low-VAF mutations in non-cancer tissues and a valuable resource for the community.

11 November 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
AHAndrew Haddad
Andrew Haddad
ARAparna Radhakrishnan
Aparna Radhakrishnan
SMSean McGee
Sean McGee
JSJoshua D. Smith
Joshua D. Smith
JKJason H. Karnes
Jason H. Karnes
SZStephan Zuchner
Stephan Zuchner
Pharmacogenomics promises improved outcomes through individualized prescribing. However, the lack of diversity in pharmacogenomics studies impedes clinical translation and the application of precision medicine across populations. We evaluated the frequencies of variants in 16 pharmacogenes ( ABCG2 , CACNA1S , CYP2D6 , CYP2C Cluster , CYP2C19 , CYP2C9 , CYP3A5 , CYP4F2 , DPYD , G6PD , NUDT15 , RYR1 , SLCO1B1 , TPMT , UGT1A1 , and VKORC1 ) and predicted phenotypes and medication exposures using whole-genome sequencing and electronic health record data from nearly 100,000 All of Us Research Program participants. We report that 100% of participants carried at least one pharmacogenomic variant and nearly all (99.5%) had a predicted phenotype with prescribing recommendations. Clinical impact was high with 24.4% of participants having both an actionable phenotype for these pharmacogenes and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance. Importantly, we report thousands of previously unrecognized pharmacogene variants and hundreds of alleles and predicted phenotypes that deviate from known frequencies across populations or were previously unreported, especially in the Americas and African ancestry groups.